Company
Headquarters: Wuzhou, China
Employees: 3,993
CN¥7.78 Billion
CNY as of Jan. 1, 2025
US$1.07 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Guangxi Wuzhou Zhongheng Group Co., Ltd. researches, develops, manufactures, and sells pharmaceuticals in China. The company offers pills, capsules, and injections and tablets for cardiovascular and cerebrovascular diseases, bruises, gynecological diseases, and respiratory diseases. It also produces health food products under the DOUBLE MONEY brand, as well as health-care functional beverages, smokable turtle pastes, jelly-type turtle paste, etc. The company is based in Wuzhou, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥2.86 B |
| EBITDA | CN¥481.7 M |
| Gross Profit TTM | CN¥1.24 B |
| Profit Margin | -0.87% |
| Operating Margin | -7.27% |
| Quarterly Revenue Growth | -24.80% |
Guangxi Wuzhou Zhongheng Group Co.,Ltd has the following listings and related stock indices.
Stock: SSE: 600252 wb_incandescent